Press Releases May 13, 2026 09:00 AM

Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference

Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CHE

Chemed Corporation announced it will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026. The presentation will be webcast live and available for replay. Chemed operates two subsidiaries: VITAS Healthcare, a leader in hospice care, and Roto-Rooter, a provider of plumbing services.

Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
CHE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Chemed will present at a major healthcare investment conference, providing an opportunity to update investors on its business.
  • Chemed operates two key subsidiaries impacting healthcare and home services sectors: VITAS Healthcare (hospice care) and Roto-Rooter (plumbing services).
  • The webcast allows broad investor accessibility and enhances transparency about Chemed’s operations and strategy.

CINCINNATI, May 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at approximately 8:30 a.m. (ET) at The InterContinental New York Barclay Hotel in New York City.  

The audio webcast can be accessed by visiting the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours after the live presentation and will be accessible for 90 days.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT:
Michael D. Witzeman                               
(513) 762-6714


Risks

  • Forward-looking statements highlight risks that actual results may differ materially due to inherent business uncertainties.
  • Market conditions and operational challenges in healthcare and home services sectors may impact the company’s performance.
  • No new financial or operational information is provided in this announcement, limiting immediate impact on market sentiment.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026